Valuation: Protara Therapeutics, Inc.

Market Cap 156M 141M 131M 118M 222M 14.69B 230M 1.57B 622M 7.85B 585M 572M 24.9B P/E 2026 *
-1.85x
P/E 2027 * -1.64x
Enterprise Value 156M 141M 131M 118M 222M 14.69B 230M 1.57B 622M 7.85B 585M 572M 24.9B EV / Sales 2026 *
-
EV / Sales 2027 * 134x
Free-Float
97.79%
Yield 2026 *
-
Yield 2027 * -
11-06 Proteon Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 CI
11-06 Protara Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 CI
10-15 Protara Therapeutics, Inc. Completes Enrollment of the Phase 2B Open-Label Dose Confirmation Phase of the Thrive-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support CI
08-11 Protara Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
06-30 Protara Therapeutics CMO Leonardo Viana Nicacio Resigns MT
06-29 Protara Therapeutics, Inc. Announces Executive Changes, Effective June 26, 2026 CI
05-28 Protara Therapeutics - enters sales agreement with TD Cowen for common stock offering RE
05-20 Oppenheimer Adjusts Protara Therapeutics PT to $28 From $25, Maintains Outperform Rating MT
05-19 Protara Therapeutics, Inc. - Special Call
05-15 Protara Therapeutics, Inc. Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 Advanced-2 Trial of TARA-002 in NMIBC CI
05-15 Protara Therapeutics announces positive updated 12-month data demonstrating durable responses RE
05-13 Protara Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-27 Protara Therapeutics, Inc. to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting CI

Last Transcript: Protara Therapeutics, Inc.

1 day+3.69%
1 week+10.00%
Current month+2.02%
1 month+5.42%
3 months-36.27%
6 months-50.39%
Current year-52.53%
1 week 2.33
Extreme 2.33
2.7
1 month 2.09
Extreme 2.09
2.7
Current year 2.09
Extreme 2.09
7.5
1 year 2.09
Extreme 2.09
7.82
3 years 1.04
Extreme 1.04
10.48
5 years 1.04
Extreme 1.04
10.48
10 years 1.04
Extreme 1.04
67.08
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 45 2019-02-28
Chief Executive Officer 54 2017-10-31
Director of Finance/CFO 58 2023-01-29
Director TitleAgeSince
Chairman 67 2019-12-31
Director/Board Member 68 2019-12-31
Director/Board Member 60 2019-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
6/30/26 Don

Founder

-30,000 0.0534%
6/15/26 Free

Director

31,000 0.0552%
6/15/26 Free

Director

31,000 0.0552%
Change 5-day change 1-year change 3-year change Capi.($)
+3.69%+10.00%-54.08%+110.83% 156M
-2.69%-0.48%+53.97%+66.82% 66.33B
-0.92%+7.67%+12.64%+93.22% 60.62B
0.00%+0.39%+22.34%+89.58% 55.5B
+0.14%+2.35%+13.86%+111.94% 47.58B
-2.21%-2.47%+20.18%+28.81% 43.69B
-2.30%-10.40%+154.30%+707.36% 37.27B
+2.15%+1.42%+14.58%+48.71% 36.57B
-2.32%-2.24%+76.50%+56.02% 32.22B
+2.62%+5.90%-37.29%+386.59% 26.58B
Average -0.18%+1.05%+27.70%+169.99% 41B
Weighted average by Cap. -0.83%+0.20%+36.59%+152.22%

Financials

2026 *2027 *
Net sales - 1.17M 1.06M 978K 882K 1.66M 110M 1.72M 11.75M 4.66M 58.76M 4.38M 4.29M 187M
Net income -83.76M -75.91M -70.21M -63.35M -119M -7.9B -124M -843M -334M -4.22B -314M -308M -13.39B -106M -96.17M -88.95M -80.25M -151M -10.01B -157M -1.07B -424M -5.34B -398M -390M -16.97B
Net Debt - -
Projected Income Statement - Annual - Protara Therapeutics, Inc.
Logo Protara Therapeutics, Inc.
Protara Therapeutics, Inc. is a clinical-stage biotechnology company focused on advancing transformative therapies for people with cancer and rare diseases. The Company's portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin, as well as a Phase II trial in pediatric patients with LMs. TARA-002 is a first-in-class TLR2/NOD2 agonist and novel immunopotentiator derived from inactivated Streptococcus pyogenes. Additionally, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral support who are otherwise unable to meet their choline needs via oral or enteral routes.
Employees
46
Date Price Change Volume
26-11-13 US$2.530 +3.69% 728,220
26-11-12 US$2.440 -6.87% 1,135,276
26-11-11 US$2.620 +7.82% 766,179
26-11-10 US$2.430 -3.19% 460,645
26-11-09 US$2.510 +9.13% 915,047
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Protara Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.530USD
Average target price
25.33USD
Spread / Average Target
+901.32%
  1. Stock Market
  2. Stocks
  3. TARA Stock